2026-07-28T16:45:39+00:00 2025-09-30 346565596 ERNST & YOUNG US LLP 200 CLARENDON STREET BOSTON MA 021165072 990 2024-10-01 042263040 Dana-Farber Cancer Institute Inc DANA 6176323000 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 MICHAEL L RENEY CFO & ASSISTANT TREASURER 6176323000 2026-07-28 true George Pagano P01978122 6172662000 2026-07-24 2024 2025-03-06 01:10:19Z BENJAMIN EBERT MD PHD PRESIDENT 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 3920793349 false X WWW.DANA-FARBER.ORG X 1951 MA SEE SCHEDULE O 66 65 9731 500 0 0 779153701 775180377 2611491064 3030902186 5694108 4786266 75255837 106902430 3471594710 3917771259 7580997 8197302 0 0 1082475984 1212731474 5632350 5624710 55757821 2262455426 2598533141 3358144757 3825086627 113449953 92684632 5348876627 5997012444 1437795236 1513380172 3911081391 4483632272 SEE SCHEDULE O false false 2583812037 0 3030902186 CLINICAL CARE - SEE SCHEDULE O 835998547 0 0 RESEARCH - SEE SCHEDULE O 49344471 8197302 0 COMMUNITY BENEFITS - SEE SCHEDULE O 3469155055 true true false true false false false false false true true false false true true false false true false false true false false true true false true true true true true true false false false false false true false false false false true false false false true true true true true false true X 1048 0 true 9731 true true true true KS false false false true true false false false false true false X 66 65 true false false false false false false true true false false false true true true true true true true true false false CA FL GA AL IL KS KY MD MA MN MS NH NJ NM NY NC OR SC TN WI X MELISSA CHAMMAS 6176323000 450 BROOKLINE AVE BP418 BOSTON MA 02115 Benjamin Ebert MD PhD TRUSTEE, PRESIDENT, & CEO (AS OF 10/1/24) 43.0 7.0 X X 468091 0 63424 JOSHUA BEKENSTEIN Trustee & Chairman 2.0 3.0 X X 0 0 0 Lori Whelan Trustee, Treasurer 2.0 3.0 X X 0 0 0 Monica Chandra Trustee & Secretary 1.0 1.0 X X 0 0 0 Richard Lubin Trustee & Vice-Chairman 2.0 0 X X 0 0 0 Afsaneh Beschloss Trustee 1.0 0 X 0 0 0 Alison Jaffe Trustee 1.0 0 X 0 0 0 Amy Berylson Trustee 1.0 0 X 0 0 0 Amy Kyle ESQ Trustee 1.0 0 X 0 0 0 Andrew Janower Trustee 1.0 0 X 0 0 0 Andrew Kaplan Trustee 1.0 0 X 0 0 0 Beth Terrana Trustee 1.0 0 X 0 0 0 Betty Ann Blum Trustee 1.0 0 X 0 0 0 Bradley Lucas Trustee 1.0 0 X 0 0 0 Brian Knez Trustee 1.0 0 X 0 0 0 Christopher J Hadley Trustee 1.0 0 X 0 0 0 Demond Martin Trustee 1.0 0 X 0 0 0 Doug Grip Trustee 1.0 0 X 0 0 0 Elizabeth Clymer Trustee 1.0 0 X 0 0 0 Elizabeth Rappaport Trustee (AS OF 1/27/25) 1.0 0 X 0 0 0 Eric Miller Trustee 1.0 0 X 0 0 0 Esta Stecher Trustee 1.0 0 X 0 0 0 Fatima Penrose Trustee 1.0 0 X 0 0 0 Frank Laukien PHD Trustee 1.0 0 X 0 0 0 Frederica Williams Trustee 1.0 0 X 0 0 0 Gary Prado Trustee 1.0 0 X 0 0 0 Harvey Berger MD Trustee 1.0 0 X 0 0 0 Hise Gibson Trustee 1.0 0 X 0 0 0 James McCann Trustee 1.0 0 X 0 0 0 Jane Brock-Wilson Trustee 1.0 0 X 0 0 0 Jane Jamieson Trustee 1.0 0 X 0 0 0 Jennifer Perini Trustee 1.0 0 X 0 0 0 Jessica Knez-Dulac Trustee 1.0 0 X 0 0 0 Jill Greenthal Trustee 1.0 0 X 0 0 0 Jodi Walker Trustee 1.0 0 X 0 0 0 Jose Aguerrevere Trustee 1.0 0 X 0 0 0 Karen Daley PHD MPH RN FANN Trustee 1.0 0 X 0 0 0 Karen Linde Packman Trustee 1.0 0 X 0 0 0 Kate Gulliver Trustee 1.0 0 X 0 0 0 Kenneth Lochiatto Trustee (AS OF 1/27/25) 1.0 0 X 0 0 0 Kevin DaSilva Trustee 1.0 0 X 0 0 0 Kimberly Sherman Stamler Trustee 1.0 0 X 0 0 0 Laura Sen Trustee 1.0 0 X 0 0 0 Levi Garraway MD PhD Trustee 1.0 0 X 0 0 0 Lisa Ferraro Trustee 1.0 0 X 0 0 0 Louise Svanberg Trustee 1.0 0 X 0 0 0 Meg Reynolds Trustee 1.0 0 X 0 0 0 Michael Eisenson Trustee 1.0 0 X 0 0 0 Michael Trotsky Trustee 1.0 0 X 0 0 0 Moria Forbes Trustee (END 9/22/25) 1.0 0 X 0 0 0 Nancy Gibson Trustee 1.0 0 X 0 0 0 Nancy Lotane Trustee 1.0 0 X 0 0 0 Paul Marcus Trustee 1.0 0 X 0 0 0 Payal Divakaran Trustee (AS OF 1/27/25) 1.0 0 X 0 0 0 Peter Palandjian Trustee 1.0 0 X 0 0 0 Phillip Gross Trustee 1.0 0 X 0 0 0 Robert Reynolds Trustee 1.0 0 X 0 0 0 Robert Stansky Trustee 1.0 0 X 0 0 0 Ronald Sullivan Trustee 1.0 0 X 0 0 0 Sandra Stratford MD Trustee 1.0 0 X 0 0 0 Stephen Koster ESQ Trustee (END 1/27/25) 1.0 0 X 0 0 0 Steven Koppel Trustee 1.0 0 X 0 0 0 Susan Alexander ESQ Trustee 1.0 0 X 0 0 0 Susan Poduska Trustee 1.0 0 X 0 0 0 Sushil Tuli Trustee 1.0 0 X 0 0 0 Theodore Pasquarello Trustee (END 1/27/25) 1.0 0 X 0 0 0 Timothy Cohen Trustee 1.0 0 X 0 0 0 Tracey McCain ESQ Trustee 1.0 0 X 0 0 0 William Santis MD Trustee (AS OF 1/27/25) 1.0 0 X 0 0 0 Jennifer Willcox ESQ Asst Secretary & General Counsel 50.0 0 X 872309 0 85729 Michael L Reney CFO & Assistant Treasurer 46.0 4.0 X 1217752 0 52171 William Hahn MD PHD COO & EVP 49.0 1.0 X 1453272 0 52093 Barrett J Rollins MD PHD Sr. Advisor to President & CEO 50.0 0 X 565346 0 60362 Craig A Bunnell MD MPH MBA Chief Medical Officer 50.0 0 X 1066683 0 89863 Jeffrey Meyerhardt MD MPH Chief Clinical Research Officer 48.0 2.0 X 752787 0 92059 Kevin Haigis PHD Chief Scientific Officer 50.0 0 X 691806 0 52050 Maria Megdal SVP Chief Administrative Officer 50.0 0 X 649630 0 107407 Melany Duval SVP & Chief Philanthropy Officer 50.0 0 X 1154110 0 71100 Naomi Lenane SVP INFORMATION SERVICES CIO 50.0 0 X 169338 0 29312 Patrick McCormick SVP HOSPITAL TRANSFORMATION 50.0 0 X 394169 0 10879 Sylvia A Bartel RPh MHP SR. VP of Pharmacy & CPO 50.0 0 X 374157 0 88635 Wendy Gettleman VP of Facilities Management & Real Estate 50.0 0 X 400510 0 91933 George D Demetri MD PROFESSOR 50.0 0 X 781464 0 72016 Laurie H Glimcher MD President & CEO Emerita 50.0 0.0 X 2313019 0 366631 Michael Constantine MD Milford Med Dir-Hematology/Oncology 50.0 0 X 831650 0 93119 Robert Soiffer MD Chief Clinical Program Officer 50.0 0 X 882186 0 71734 Scott Armstrong MD PHD Chair of Pediatric Oncology 50.0 0 X 843326 0 84542 Bruce Johnson MD Former 0.0 0 X 290667 0 42086 John O Chesley ESQ Former Officer 0.0 0 X 417532 0 172 16589804 0 1677317 2997 true true false BRIGHAM AND WOMEN'S HOSPITAL 399 Revolution Drive Ste 645 SOMERVILLE MA 02145 MEDICAL SERVICES 232320543 CARDINAL HEALTH 7611 Brandon Woods Blvd Baltimore MD 21226 MEDICAL SERVICES 68336278 South Shore Hospital 55 Fogg Rd South Weymouth MA 02190 Medical Services 37936394 Advanced Accelerator Applications USA Inc 350 Fifth Avenue New York NY 10118 Radiotherapy 28320273 WALSH BROTHERS INC 200 COMMERCIAL ST BOSTON MA 02109 BUILDING CONTRACTOR 17494540 686 109974 17154286 1340898 187288946 569286273 31139415 775180377 NET PATIENT SERVICE REVENUE 621110 3014499786 3014499786 NETWORK COLLABORATION 900099 12681408 12681408 LINAC 621500 3720992 3720992 0 0 0 0 3030902186 4786266 4786266 88911113 88911113 1419015 1419015 0 1419015 1419015 0 0 572369 17154286 3022090 -2449721 -2449721 FOOD SERVICE REVENUE 722514 5775906 5775906 PARKING LOT REVENUE 812930 5063047 5063047 Surplus Capital Distribution 524298 4005132 4005132 4177938 0 0 4177938 19022023 3917771259 3030902186 0 111688696 4518181 4518181 3679121 3679121 0 0 10229960 3450779 5625071 1154110 3021218 290667 2730551 0 949518738 798430669 118340857 32747212 61957100 51622155 8153294 2181651 121441680 101184227 15907202 4350251 66562778 55459569 8759382 2343827 6147923 5185353 962570 0 20276028 10916885 9350230 8913 922472 0 922472 0 1128432 1128432 0 0 5624710 5624710 131522532 100290367 30184854 1047311 16565913 10181658 4839898 1544357 14842682 9197461 4165101 1480120 96972569 88049849 8767639 155081 174982892 148634938 26345798 2156 13285255 12167227 957091 160937 7141445 2642956 2931666 1566823 23244440 22742170 502270 0 98740404 83319822 15420582 0 9522081 8663 9513418 0 PHARMACEUTICALS 1606226432 1606226432 0 0 Medical Supplies Expense 155112717 154746233 366484 0 OTHER PATIENT CARE EXPENSE 49831525 49831525 0 0 BAD DEBT EXPENSE 1646424 1646424 0 0 170420975 143603292 25427321 1390362 3825086627 3469155055 300173751 55757821 81120933 121275037 81609743 70592422 338818104 343804929 488479 951018 0 0 87864118 105877230 137272053 158869947 2383471357 1294235552 985863110 1089235805 0 0 7894580 7894580 3627945507 4098511476 5348876627 5997012444 253302762 281073287 479709000 472286000 0 0 67364000 65255000 637419474 694765885 1437795236 1513380172 X 2005198802 2368122196 1905882589 2115510076 3911081391 4483632272 5348876627 5997012444 X 92684632 479866249 X false true true true true X 726297460 702430542 761032475 779153701 775180377 3744094555 0 0 726297460 702430542 761032475 779153701 775180377 3744094555 0 3744094555 113415703 44851524 334501187 70209024 95116394 658093832 93395 65661 0 41707 0 200763 7706225 13596972 16868465 14507380 19594390 72273432 4474662582 11404818951 0.83673 0.84037 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - PARKING LOT REVENUE, COLUMN A - 3167144.0, COLUMN B - 4721708.0, COLUMN C - 4855402.0, COLUMN D - 4997539.0, COLUMN E - 5063047.0, COLUMN F - 22804840.0; DESCRIPTION - FOOD SERVICE REVENUE, COLUMN A - 2516332.0, COLUMN B - 3633966.0, COLUMN C - 4388191.0, COLUMN D - 5102880.0, COLUMN E - 5775906.0, COLUMN F - 21417275.0; DESCRIPTION - SURPLUS CAPITAL DISTRIBUTION, COLUMN A - 0.0, COLUMN B - 1820768.0, COLUMN C - 0.0, COLUMN D - 0.0, COLUMN E - 4005129.0, COLUMN F - 5825897.0; DESCRIPTION - MISCELLANOUS REVENUE, COLUMN A - 1067783.0, COLUMN B - 2815275.0, COLUMN C - 3125300.0, COLUMN D - 2921265.0, COLUMN E - 2613948.0, COLUMN F - 12543571.0; DESCRIPTION - FUNDRAISING EVENTS, COLUMN A - 256368.0, COLUMN B - 605255.0, COLUMN C - 499572.0, COLUMN D - 480682.0, COLUMN E - 572369.0, COLUMN F - 2414246.0; DESCRIPTION - DISTRIBUTION FROM DFMGBCC, COLUMN A - 0.0, COLUMN B - 0.0, COLUMN C - 4000000.0, COLUMN D - 0.0, COLUMN E - 0.0, COLUMN F - 4000000.0; DESCRIPTION - BOUTIQUE, COLUMN A - 698598.0, COLUMN B - 0.0, COLUMN C - 0.0, COLUMN D - 1005014.0, COLUMN E - 1563991.0, COLUMN F - 3267603.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true true false false false true 742454 true 385978 false false 1128432 false Schedule C, Part II-B ALLIANCE OF DEDICATED CANCER CENTERS REPRESENTS THE NATION'S TEN FREESTANDING CANCER CENTERS. WE WORK TOGETHER ON FEDERAL REGULATORY, LEGISLATIVE, AND REIMBURSEMENT ISSUES UNIQUE TO DEDICATED CANCER CENTERS. A PORTION OF THE MEMBERSHIP DUES ARE USED FOR LOBBYING ACTIVITIES. ALSTON & BIRD LLP PROVIDED FEDERAL LEGISLATIVE CONSULTING FOR DFCI. DFCI IS A MEMBER OF THE AMERICAN HOSPITAL ASSOCIATION, A NOT-FOR-PROFIT ORGANIZATION THAT REPRESENTS AND ADVOCATES FOR THE COLLECTIVE INTERESTS OF THEIR MEMBERS THROUGH PUBLIC ADVOCACY, EDUCATION, AND INFORMATION. ON OCCASION, DFCI EXECUTIVE LEADERSHIP MEET WITH STATE AND FEDERAL ELECTED OFFICIALS TO ADVOCATE FOR THE PASSAGE OF LEGISLATION AND FUNDING TO ADVANCE CANCER RESEARCH AND TREATMENT, AND LEGISLATION TO SUPPORT SERVICES FOR CANCER PATIENTS AND CANCER SURVIVORS. IN ADDITION, DFCI SUBMITS LETTERS AND/OR TESTIMONY TO ELECTED OFFICIALS AND POLICY MAKERS ON THESE ISSUES. A PORTION OF THE MEMBERSHIP DUES ARE USED FOR LOBBYING ACTIVITIES. DFCI IS A MEMBER THE AMERICAN ASSOCIATION OF MEDICAL COLLEGES WHICH FOCUSES ON TRANSFORMING HEALTH CARE IN FOUR PRIMARY MISSION AREAS: MEDICIAL EDUCATION, BIOMEDICAL RESEARCH, CLINICAL CARE, AND COMMUNITY COLLABORATIONS. THEY ARE THE LEADING VOICE OF THE NATION'S MEDICAL SCHOOLS, ACADEMIC HEALTH SYSTEMS, AND ACADEMIC SOCIETIES WITH THE PUBLIC AND BEFORE CONGRESS, FEDERAL REGULATORY AGENCIES, AND THE EXECUTIVE BRANCH. A PORTION OF THE MEMBERSHIP DUES ARE USED FOR LOBBYING ACTIVITIES. CONFERENCE OF BOSTON TEACHING HOSPITALS PROVIDED STATE AND FEDERAL LOBBYING SUPPORT TO DFCI. CQ ROLL CALL PROVIDES GRASSROOTS ADVOCACY SOFTWARE USED FOR EMAILS AND ACTION ALERTS ON ADVOCACY ISSUES WHICH ARE SENT TO MEMBERS OF DANA-FARBER'S LEGISLATIVE ACTION NETWORK(LAN). DFCI'S LAN ADVOCATES FOR LEGISLATION AND POLICIES THAT IMPROVE THE LIVES OF CANCER PATIENTS. DFCI IS A MEMBER OF THE MASSACHUSETTS BUSINESS ROUNDTABLE WHICH IS A PUBLIC POLICY ORGANIZATION THAT HAS DONE EXETENSIVE POLICY WORK ON EDUCATION, HEALTH CARE, COMPETITIVENESS, WORKFORCE DEVELOPMENT, SOCIAL AND INFRATSTRUCTURE ISSUES THAT HAVE BROAD IMPACT ON THE SOCIAL AND ECONOMIC WELLBEING OF THE COMMONWEALTH. A PORTION OF THE MEMBERSHIP DUES ARE USED FOR LOBBYING ACTIVITIES. DFCI IS A MEMBER OF THE MASSACHUSETTS HEALTH AND HOSPITAL ASSOCIATION. THE MHA SERVES AS THE UNIFIED VOICE FOR THE COMMONWEALTH'S HOSPITALS, HEALTH SYSTEMS, AND HEALTHCARE PROVIDERS THROUGH ADVOCACY, INFORMATION AND EDUCATION, COLLABORATION. A PORTION OF THE MEMBERSHIP DUES ARE USED FOR LOBBYING ACTIVITIES. DFCI IS A MEMBER OF THE MASSACHUSETTS TAXPAYER FOUNDATION WHICH IS WIDELY RECOGNIZED AS THE STATE'S PREMIER PUBLIC POLICY ORGANIZATION DEALING WITH STATE AND LOCAL FISCAL, TAX, AND ECONOMIC POLICIES. A PORTION OF THE MEMBERSHIP DUES ARE USED FOR LOBBYING ACTIVITIES. MCDERMOTT, QUILTY, MILLER & HANLEY, LLP PROVIDED STATE LEGISLATIVE AND GOVERNMENT RELATIONS CONSULTING FOR DFCI. DFCI IS A MEMBER OF THE NEW ENGLAND COUNCIL WHICH IS A NON-PARTISAN ALLIANCE OF BUSINESSES, ACADEMIC AND HEALTH INSTITUTIONS, AND PUBLIC AND PRIVATE ORGANIZATIONS THROUGHOUT NEW ENGLAND FORMED TO PROMOTE GROWTH AND QUALITY OF LIFE IN THE NEW ENGLAND REGION; BY ARTICULATING THE VOICE REGIONALLY AND NATIONALLY ON F IMPORTANT ISSUES FACING NEW ENGLAND. TSK ASSOCIATES PROVIDES STATE LEGISLATIVE AND GOVERNMENT RELATIONS CONSULTING FOR DFCI. 526463000 23900000 74620000 30589000 594394000 458787000 21098000 77016000 30438000 526463000 430270000 18963000 38462000 28908000 458787000 479196000 29347000 -55371000 22902000 430270000 357421000 14528000 122237000 14990000 479196000 0.0 0.582 0.418 false true true 17067029 17067029 1388362740 812421711 575941029 401353204 198115730 203237474 370459310 283698111 86761199 206229074 206229074 1089235805 INTEREST IN DANA-FARBER, INC. 3554753508 RIGHT OF USE - NET OPERATING LEASES 386864177 RESEARCH RECEIVABLES 81365677 MISCELLANEOUS ASSETS 75528114 4098511476 Federal Income Taxes OPERATING LEASE LIABILITIES 417874193 RESEARCH ADVANCES 171107436 AMOUNTS DUE THIRD PARTY PAYOR 70494752 SWAP VALUATION LIABILITY 16716692 MISCELLANEOUS LIABILITIES 16307812 PROVISION FOR MEDICAL MALPRACTICE CLAIMS 2265000 694765885 0 0 0 0 0 0 0 0 0 0 0 0 Schedule D, Part V, Line 4 Intended uses of endowment funds DANA-FARBER, INC. (DFI) A RELATED ORGANIZATION OF DANA-FARBER CANCER INSTITUTE, INC. (DFCI) HOLDS THE ENDOWMENTS FOR DFCI. AS DESCRIBED IN THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS, DFCI'S ENDOWMENTS CONSIST SOLELY OF DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR PURPOSES DIRECTLY RELATED TO DFCI'S EXEMPT MISSION AND PURPOSES. AS REQUIRED BY GENERALLY ACCEPTED ACCOUNTING PRINCIPLES, NEW ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OF DONOR-IMPOSED RESTRICTIONS. ALL USES OF DFCI'S ENDOWMENT FUNDS ARE IN FURTHERANCE OF DFCI'S EXEMPT MISSION AND PURPOSES. Europe (Including Iceland and Greenland) 0 0 Program Services Subcontracted Research 4057000 South Asia 0 0 Program Services Subcontracted Research 728000 East Asia and the Pacific 0 0 Program Services RESEARCH AND EDUCATION 696000 South America 0 0 Program Services RESEARCH AND EDUCATION 629000 North America (Canada & Mexico only) 0 0 Program Services Subcontracted Research 602000 East Asia and the Pacific 0 0 Program Services Subcontracted Research 600000 Sub-Saharan Africa 0 0 Program Services Subcontracted Research 237000 Middle East and North Africa 0 0 Program Services Subcontracted Research 170000 Middle East and North Africa 0 0 Program Services RESEARCH AND EDUCATION 220000 South America 0 0 Program Services Subcontracted Research 27000 0 0 0 0 0 0 7966000 0 7966000 false false false false false true Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual; SUB-SAHARAN AFRICA-Accrual X X X X X X X true Moore a Series LLC 4200 PARLIAMENT PLACE THIRD FLOOR LANHAM MD 20706 DIRECT MAIL false 5982709 3721597 2261112 Charles River Interactive Inc 900 Chelmsford St Tower III 10th fl LOWELL MA 01851 social media consulting false 1890571 -1890571 In Voices LLC dba Good to Go 314 ELLIOT ST MILTON MA 02186 NEW SPECIAL EVENT AND ONLINE FUNDRAISING STRATEGIES false 5000 -5000 Huron Consulting Group Inc 550 W Van Buren Street CHICAGO IL 60607 Consulting false 7543 -7543 5982709 5624711 357998 CA CO CT DC FL GA AL HI IL KS KY LA ME AK MD MA MI MN MS MO NV NH NJ NM NY NC ND OH OK OR PA RI SC TN VA AR WA WV WI BMJF Walk 11069349 10880404 188945 0 5452 63034 23705 2042325 RADIO-TELETHON 5812665 5812665 0 0 10656 3032 0 411740 5 844641 461217 383424 725 58190 30557 2752 369922 17726655 17154286 572369 725 74298 96623 26457 2823987 3022090 -2449721 true true X true X true X true true true false true true 41227994 26990025 14237969 0.00372 209061318 134279477 74781841 0.01956 0 0.0 0 0 250289312 161269502 89019810 0.02328 13467742 13467742 0.00352 8636576 1634961 7001615 0.00183 0 0.0 910295134 716661377 193633757 0.05064 4260338 4260338 0.00111 0 0 936659790 718296338 218363452 0.05711 0 0 1186949102 879565840 307383262 0.08039 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0 0 0 0.0 true 1646424 16464 619296139 705286268 -85990129 X true true 1 1 DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVE BOSTON MA 02215 WWW.DANA-FARBER.ORG 2335 X X X DANA-FARBER CANCER INSTITUTE INC 1 false false true X X X X X X X X X 25 true false false true X https://www.dana-farber.org/community-health/community-health-needs-assessment X true 26 true HTTPS://WWW.DANA-FARBER.ORG/COMMUNITY-HEALTH/COMMUNITY-HEALTH-NEEDS-ASSESSMENT false true X 150.0 300.0 X true true X X X true X https://www.dana-farber.org/patient-family/support-services/patient-financial-assistance X https://www.dana-farber.org/patient-family/support-services/patient-financial-assistance X https://www.dana-farber.org/patient-family/support-services/patient-financial-assistance X X X X X X true X false X X X true X false false Schedule H, Part V, Section B, Line 5 Facility , 1 Facility , 1 - Dana-Farber Cancer Institute ("DFCI"). In 2025, Dana-Farber's Board of Trustees approved the 2025-2028 Cancer-Focused Community Health Needs Assessment (CHNA) and Implementation Plan to ensure that our collective efforts have the maximum possible impact within the Institute's priority neighborhoods. Dana-Farber's Community Benefits Office retained Health Resources in Action (HRiA), a non-profit public health consultancy organization in Boston, to undertake a comprehensive assessment of the health needs within our priority communities, including how those needs are currently being addressed and where there are opportunities to address these needs in the future. The 2025 CHNA and CHIP build on previous efforts and examine the cancer burden across Boston, both overall and among specific population groups. The CHNA and CHIP are grounded in Dana-Farber's commitment to health equity and to addressing social determinants of health (SDoH). As such, this implementation plan aims to be actionable to better support individuals from all backgrounds across the cancer care continuum. The 2025 Dana-Farber CHNA identified multiple geographies and populations who are disproportionately impacted by cancer, access to screenings, and the social and economic factors that give rise to these health disparities. These include the neighborhoods of Dorchester, Mattapan, Roxbury, Mission Hill, Jamaica Plain and East Boston and communities of color, non-English speaking residents, immigrants, low-income residents, people with disabilities, and LGBTQIA+ residents. Dana-Farber is an active member of the Boston Community Health Collaborative (the Collaborative), which is a partnership of Boston health institutions, the Boston Public Health Commission, community health centers, and community organizations working to improve the health and well-being of Boston residents. The Collaborative conducted a large-scale city-wide CHNA in 2025 and many findings from this effort are integrated into this implementation plan particularly in relation to health equity and the social determinants of health. In June 2025, findings from the Boston Community Health Needs Assessment were formally presented to the Dana-Farber Trustees Community Programs Committee and the Dana-Farber Community Benefits External/DoN Advisory Committee. The presentations highlighted citywide trends, inequities, and priority community needs, and helped contextualize and inform Dana-Farber's community health planning and alignment with the upcoming CHNA and CHIP. This alignment ensures that Dana-Farber remains responsive to immediate community needs and supports flexibility and readiness to address issues that might arise in the future. This integrated approach provides a deeper context for cancer-related experiences across Boston's communities. The Collaborative's Needs Assessment and Improvement Plan can be found here: https://www.boston.gov/government/cabinets/boston-public-health-commission/racial-justice-and-health-equity/bostonchna The 2025 Dana-Farber Cancer CHNA uses multiple data sources including data already collected via existing sources (secondary data) and new information gathered for this specific effort (primary data). As noted, this report also incorporates data from the citywide Boston CHNA. The following provides an overview of the methods employed in the 2025 DFCI CHNA and a highlight of the Boston CHNA methods that were incorporated into this report. Please see the 2025-2028 DFCI CHNA Appendix A for a more detailed description of these methods and their limitations and Appendix B for more information on data analyses. Primary data are new data collected specifically for the CHNA. Primary data were collected using 2 different methods: community resident focus groups and a key informant survey. Focus groups for the Dana-Farber Cancer CHNA were carried out in collaboration with community partners in surrounding neighborhoods, including Mission Hill, Dorchester, and East Boston. 91 cancer patients, survivors, and caregivers engaged in 9 focused discussions from February - April 2025. Dana-Farber made introductions and connections for some of these groups. Focus groups were conducted both in-person (90 minutes) and virtually (60-90 minutes) and aimed to delve deeply into experiences with cancer screening, treatment and care coordination, and survivorship. Focus groups were conducted with the following population groups: English-speaking men who specifically are prostate cancer patients/survivors and their caregivers; Latinx residents who speak Spanish (2 groups); Asian residents who speak Cantonese; Asian residents who speak Vietnamese; Residents who speak English (3 groups); Residents who identify as LGBTQIA+. The following community partners assisted with recruiting participants and/or hosting focus groups: Asian Women for Health, DFCI LGBTQIA+ Patient Support Group, Prostate Health Education Network, Roxbury Tenants of Harvard, Union Capital Boston, and VietAID. Focus group notes were coded and analyzed using NVivo, a qualitative analysis software, to identify major categories and sub-themes that emerged across all groups, as well as unique issues specific to particular populations. The frequency and intensity of discussions on a topic were the key drivers used for extracting main themes. Selected de-identified paraphrased quotes are presented to further illustrate points within topic areas. Additionally, 24 providers, organizational leaders, and community residents completed an open-ended key informant survey. The Dana-Farber Key Informant Survey aimed to collect information about key stakeholders' perceptions of community resources and opportunities for improvement. The survey was offered between March - April 2025 to medical providers, navigators, staff from community-based organizations focused on cancer care, and community residents touched by cancer. These individuals were pre-selected by Dana-Farber for their cancer-related expertise. Targeted outreach was conducted primarily through email. The survey tool included 8 open-ended questions and was made available online through Qualtrics in English. In this report, people who completed the survey are referred to as "key informant survey respondents" (whereas those who were part of focus groups are referred to as "participants" for distinction). The final sample includes 24 key informant survey respondents. NVivo was also used to analyze the open-ended survey responses, employing a similar qualitative coding process used for the focus group data noted above. Secondary data are data that has already been collected for another purpose. Examining secondary data helps us to understand trends, provide a baseline, and identify differences by sub-groups. These quantitative findings help guide the methods and populations for primary data collection. As an example, populations for focus groups were prioritized among those groups with the largest cancer burden, lowest screening rates, and challenges with healthcare access. Secondary data for this CHNA were gathered to understand cancer outcomes, risk behaviors, and social determinants of health. Existing data were drawn from national, state, and city sources, including the Boston Behavioral Risk Factor Surveillance Survey (BBRFSS), Massachusetts Department of Public Health, Boston Resident Deaths, U.S. Census American Community Survey (ACS), and Healthy People 2030. Schedule H, Part V, Section B, Line 5 Facility , 2 Facility , 2 - Dana-Farber Cancer Institute ("DFCI"). Secondary data from the Massachusetts Cancer Registry, Boston Resident Deaths, and Boston Behavioral Risk Factor Surveillance Survey (BRFSS) were analyzed by the Boston Public Health Commission's Center for Public Health Sciences and Innovation. Other data were analyzed by the organizations cited in the data source. Analyses are presented as frequencies (percentages) and rates throughout the report. Data from the surveillance systems, such as the BBRFSS, are presented with 95% confidence intervals (indicating 95% confidence that true value is in the range; noted as error bars in the figures), where possible. Time series analyses examined cancer rates over time across multiple time points. When statistical significance testing was conducted, it is noted in figures or in text. Specifically, when the word "significantly" is used in the text it connotes statistical significance (p<0.05). The following recent presentations and articles from Dana-Farber provided detailed data on specific topics and populations: 2024 Massachusetts Comprehensive Cancer Coalition Statewide Cancer Summit, The Lancet Oncology Disabilities and Cancer Series, Cancer Disparities Experienced by People with Disabilities, Dana-Farber Cancer Institute Intro to Cancer Genetic Counseling, Dana-Farber Cancer Institute Prevent Cancer Dialogue, and Dana-Farber Cancer Institute Inclusion, Diversity, and Equity in Action (IDEA) Lecture Series. Key themes from these related materials were summarized and embedded into relevant sections in the report. The description below is an overview of the Boston CHNA methods, given many findings were included in Dana-Farber's CHNA report. The Boston CHNA Community Survey aimed to collect information about Boston residents' perceptions of community strengths, priority health issues, and access to care and vital resources contributing to health and well-being. The Boston CHNA survey was offered between September 2024 and January 2025 to individuals aged 14 and up living in Boston. The anonymous survey was made available online and in paper format in English and 8 languages in addition to English (Arabic, Cape Verdean Creole, Haitian Creole, Portuguese, Spanish, Simplified Chinese, Somali, and Vietnamese). Intensive community outreach was conducted. Outreach was conducted through various means, including in-person outreach, email distribution, social media and online survey promotion. Building on previous processes, the Boston Community Health Collaborative leveraged a large, existing network of community partners who distributed the survey in online and paper formats. In addition, targeted outreach and paper survey distribution were conducted at 43 community events and locations, including farmer's markets, health fairs, block parties, public libraries, food pantries, and community meetings. Promotional flyers were distributed in all 9 survey languages.The final survey tool included 28 questions. The final sample of the CHNA Community Survey comprises 1,866 respondents who were Boston residents. 8 focus groups were conducted with specific communities of focus from December 2024 through February 2025. A total of 62 community residents participated in focus groups. Focus groups were conducted with the following population groups: South Boston mothers (in Spanish); Chinese older adults (in Cantonese); Residents in active substance use recovery; New immigrants and/or English language learners; Residents who live in Boston Housing Authority housing; Somali parents of children with special healthcare needs (in Somali); Fathers and men of color; Refugee youth. Additionally, 5 sector-based focus groups were conducted with 28 organizational partners and direct service providers. The sectors and topic areas for these groups were: Climate Justice, Housing, Community Health Workers, Mental/Behavioral Health, and Economic Mobility. These discussions aimed to focus in particular on community needs, assets, and promising practices or recommendations for action.Additionally, a total of eleven key informant interviews were completed with 13 individuals between January and March 2025. Schedule H, Part V, Section B, Line 11 Facility , 1 Facility , 1 - Dana-Farber Cancer Institute ("DFCI"). The goals and strategies outlined in the 2025-2028 Implementation Plan are specifically designed to recognize the milestones we have reached thus far, address new findings based on emerging public health research, and continue the work of achieving the goals we have set to help meet the health needs of our surrounding communities. As part of our approach to implementing the identified strategies, we will continue our existing community-based programming, which includes assessing the most effective evidence-based interventions, collaborating with community partners to implement community health improvement efforts, and conducting ongoing evaluation of program effectiveness. Our expertise as a comprehensive cancer center leads us to focus largely on reducing cancer incidence and mortality among medically underserved populations through our clinical community screening and outreach programs, which include mobile mammography and breast health education, skin cancer education and screening, HPV education and vaccination, tobacco cessation and increasing awareness about survivorship in communities of color. The 2025-2028 Implementation Plan focuses on the following areas: 1) Cancer Screening (Routine, Underutilized, and Emerging): Increasing access to and uptake of cancer screenings, particularly among populations experiencing lower screening rates; 2) Access to Care: Improving awareness, navigation, and access to timely, high-quality care across the cancer continuum; 3) Cancer Care Coordination and Treatment: Enhancing patient navigation, care coordination, and support throughout diagnosis, treatment, and survivorship; and 4) Social Determinants of Health: Addressing upstream factors - including food access, economic mobility, healthy living, and housing - that influence cancer risk and outcomes. Dana-Farber is a comprehensive cancer care specialty hospital committed to supporting communities across the cancer continuum, with a particular focus on marginalized populations. While the CHNA revealed a broad range of needs, this implementation plan focuses on areas where Dana-Farber's expertise, clinical capacity, and resources can have the greatest impact. Dana-Farber's leadership is committed to sustaining the resources required to advance these Community Health priorities and to strengthening efforts that reduce cancer disparities and improve health outcomes in the communities we serve. Dana-Farber remains engaged in broader public health efforts. As an active leader in the Collaborative, Dana-Farber collaborates with partners to address root causes of health inequities and to advance shared goals that extend beyond cancer care. While needs such as childcare or substance use may fall outside Dana-Farber's primary cancer-focused scope, we recognize their connection to the cancer care continuum, and they will be addressed at the individual patient level. Considerable progress has been made in advancing the goals set in our 2022-2025 CHNA Implementation Plan. Community Health efforts increased preventive screening and improved treatment access, deepened culturally and linguistically responsive outreach and education, and advanced policy and systems changes that addressed root causes of health inequities. The highlights summarized below reflect key accomplishments and demonstrate the collective impact of our work. * Delivered 6,784 mammograms (4,513 via the mobile van; 2,271 at Whittier Street Health Center); and worked to increase the follow-up rate for those with abnormal screening results. * Conducted skin cancer screening and provided education for 2,526 people at 49 events; 416 abnormal findings referrals and 175 biopsy referrals made; digitized an updated interactive sun safety curriculum. * Provided 208 tobacco cessation counseling sessions to seventy-five patients; 84% reduced daily cigarette use and 41% quit; supplied nicotine replacement therapy and gift cards for healthy snacks. * Engaged 1,700+ residents via virtual cancer prevention sessions with Union Capital. * Launched AssessYourRisk (AYR), a free online tool in English and Spanish, to assess risk of breast and ovarian cancers and offer resources to reduce these risks; over 14,000 AYR completions in 16 months. * Hired four bilingual Community Outreach Specialists; presented in English, Spanish, Cantonese, Mandarin, and Haitian Creole to groups including low-income residents, immigrants and men. * Expanded outreach via Chinese and Spanish media (e.g. WeChat, El Mundo). * Distributed a 7-language HPV Dental Toolkit and created LGBTQIA+- tailored education materials with Team Maureen while leading the MA HPV Coalition. * Funded and evaluated four multi-year Greater Boston non-profit organizations through DoN grantmaking focused on environmental justice, food insecurity, and child homelessness; achieved legislative wins, strengthened resident power-building and advocacy, and shared evaluation learnings at national and local meetings. * Cancer Care Access Program provided streamlined diagnostic resolution and treatment for underserved medically complex patients with suspected malignancies at three Boston FQHCs. * Expanded patient navigation to Gynecologic, Lymphoma, Myeloma, and Genitourinary cancer centers. * Strengthened Dana-Farber patient demographic data and began routine patient SOGI collection. * Earned Joint Commission Health Equity Certification. * Secured state approvals for a new 300-bed inpatient cancer hospital. 9 DFBWCC AT SOUTH SHORE HOSPITAL 101 COLUMBIAN STREET SOUTH WEYMOUTH MA 02190 SATELLITE DFBWCC AT MILFORD REGIONAL MEDICAL CENTER 20 PROSPECT STREET MILFORD MA 01757 SATELLITE DFCI - CHESTNUT HILL 300 BOYLSTON STREET NEWTON MA 02459 SATELLITE DFCI - MERRIMACK VALLEY 5 BRANCH STREET METHUEN MA 01844 SATELLITE DFNH ONCOLOGY-HEMATOLOGY ELLIOTT MED CENTER 40 BUTTRICK RD S TE B LONDONDERRY NH 03053 SATELLITE DFCI-BRIGHTON CUSHING PAVILION 736 CAMBRIDGE STRE ET BRIGHTON MA 02135 SATELLITE DFCI - LIBBEY PARK 51 PERFORMANCE DRIVE WEYMOUTH MA 02189 SATELLITE DFCI - MOBILE MAMMOGRAPHY SERVICE 450 BROOKLINE AVENUE BOSTON MA 02215 SATELLITE DFCI - WHITTIER STREET HEALTH CENTER 1290 TREMONT STREET ROXBURY MA 02120 SATELLITE DANA-FARBER CANCER INSTITUTE - FOXBOROUGH 22 PATRIOT PLACE FOXBOROUGH MA 02035 SATELLITE Schedule H, Part I, Line 3c Patient education of eligibility for assistance IN ADDITION TO DETERMINING ELIGIBILITY FOR DISCOUNTED CARE BASED ON FAMILY INCOME, DFCI OFFERS ASSISTANCE TO PATIENTS WHO HAVE EXCESSIVE MEDICAL BILLS (EXCEEDING 30-40% OF FAMILY INCOME). Schedule H, Part I, Line 6a Community information THE COMMUNITY BENEFIT REPORT WAS COMPLETED BY DFCI AND IS ANNUALLY PROVIDED TO THE MASSACHUSETTS ATTORNEY GENERAL'S OFFICE, WHERE IT IS THEN MADE PUBLIC ON ITS WEBSITE. Schedule H, Part I, Line 7 State filing of community benefit report DFCI'S STATE COST REPORT WAS USED TO DEVELOP THE INSTITUTE'S COST TO CHARGE RATIO THAT WAS APPLIED TO CHARITY CARE CHARGES TO DETERMINE THE COST OF FINANCIAL ASSISTANCE (LINE 7A). LINE 7B REFLECTS THE SPECIFIC LOSS INCURRED FOR THE INSTITUTE'S MEDICAID ACTIVITY. THE INSTITUTE IS A PREEMINENT PROVIDER OF HEALTH TRAINING TO HEALTH PROFESSIONALS WHO DESIRE TRAINING IN THE SKILLS NECESSARY TO TREAT CANCER PATIENTS. THE INSTITUTE TRAINS PHYSICIANS, SCIENTISTS, MEDICAL STUDENTS AND INDIVIDUALS LOOKING TO CREATE A CAREER IN THE FIELD OF CANCER. THE AMOUNT REPORTED AS HEALTH TRAINING REPRESENT COSTS IN EXCESS OF AMOUNTS REIMBURSED BY THIRD PARTY PAYERS SUCH AS TRAINING GRANT REVENUES AND DIRECT MEDICAL EDUCATION PAYMENTS FROM THE MEDICARE PROGRAM. DEPARTMENT LEADERS SUBMIT EXPENDITURES TO COMMUNITY BENEFITS ALONG WITH A DESCRIPTION OF THE SERVICES PROVIDED TO MEDICALLY UNDERSERVED POPULATIONS. LINE 7F EXPENDITURES ARE REVIEWED BY LEADERSHIP AND IN PARTNERSHIP WITH DFCI'S OFFICE OF FINANCE, THE EXPENDITURES ARE APPROVED. THE AMOUNTS ARE CAPTURED IN THREE BUCKETS - CB EXPENDITURES (ALL PROGRAMS); LEVERAGED FUNDS (THOSE FUNDS SUPPORTED IN FULL OR PART THROUGH GRANTS/DONATIONS) AND COMMUNITY SPONSORSHIPS. Schedule H, Part V SECTION A & D DFCI'S MAIN CAMPUS IS LOCATED 450 BROOKLINE AVE., BOSTON, MA, 02115. DFCI'S SATELLITE LOCATIONS (BELOW) EACH OPERATE UNDER THE SAME HOSPITAL LICENSE. DANA-FARBER/BRIGHAM AND WOMEN'S CANCER CENTER AT MILFORD HOSPITAL, 20 PROSPECT STREET, MILFORD, MA 01757 DANA-FARBER/BRIGHAM AND WOMEN'S CANCER CENTER AT SOUTH SHORE HOSPITAL, 101 COLUMBIAN STREET, SOUTH WEYMOUTH, MA 02190 DANA-FARBER - BRIGHTON, 736 CAMBRIDGE STREET, CUSHING PAVILION, 5TH FLOOR, BRIGHTON, MA 02135 DANA-FARBER CANCER INSTITUTE - CHESTNUT HILL, 300 BOYLSTON STREET, NEWTON, MA 02459 DANA-FARBER CANCER INSTITUTE - MERRIMACK VALLEY, 5 BRANCH STREET, METHUEN, MA 01844 DANA-FARBER CANCER INSTITUTE - FOXBOROUGH, 22 PATRIOT PLACE, FOXBOROUGH, MA, 02035 DANA-FARBER CANCER INSTITUTE - LIBBEY PARK, 51 PERFORMANCE DRIVE, WEYMOUTH, MA 02189 DANA-FARBER CANCER INSTITUTE - MOBILE MAMMOGRAPHY SERVICE, 450 BROOKLINE AVENUE, BOSTON, MA 02215 DANA-FARBER CANCER INSTITUTE - WHITTIER STREET HEALTH CENTER, 1290 TREMONT STREET, ROXBURY, MA 02120 DANA-FARBER/NEW HAMPSHIRE ONCOLOGY HEMATOLOGY ALSO OPERATES A CLINICAL LOCATION AT 40 BUTTRICK ROAD, SUITE B, LONDONDERRY, NH 03053. Schedule H, Part III Section A, Lines 2 and 3 - Bad Debt Expense IN CALCULATING BAD DEBT EXPENSE, DFCI USES A COMBINATION OF ACTUAL BAD DEBT WRITE OFFS AND HISTORICAL BAD DEBT FACTORS IN DETERMINING WHICH CURRENT ACCOUNTS RECEIVABLE ARE NOT LIKELY TO BE COLLECTED. ADDITIONALLY, DFCI DETERMINES THE AMOUNT OF BAD DEBT ATTRIBUTABLE TO INDIVIDUALS WHO ARE ELIGIBLE FOR FINANCIAL ASSISTANCE BASED ON A HISTORICAL ESTIMATE OF THE PERCENTAGE OF PATIENTS THAT HAVE QUALIFIED FOR FINANCIAL ASSISTANCE, WHICH IS APPLIED AGAINST TOTAL BAD DEBT. Schedule H, Part V, Section B, Line 20d Billing and collections DANA-FARBER DOES NOT ENGAGE IN PRESUMPTIVE ELIGIBILITY FOR ITS PATIENT FINANCIAL ASSISTANCE POLICY (FAP). THROUGH ITS PARTICIPATION IN THE MASSACHUSETTS HEALTH SAFETY NET, THE STATE SPONSORED UNCOMPENSATED PROGRAM, DANA-FARBER FIRST RELIES ON DEMONSTRATION OF INELIGIBILITY FOR MASSHEALTH PROGRAMS, SUCH AS HEALTH SAFETY NET, OR SIMILAR OUT OF STATE MEDICAID PROGRAMS, FROM PATIENTS APPLYING FOR ASSISTANCE. UPON DETERMINATION BY THE STATE AGENCY, DANA-FARBER WILL CONSIDER EACH CASE INDIVIDUALLY AND RELIES ON THE COMPLETION OF THE PATIENT FINANCIAL ASSISTANCE APPLICATION ("PFA APPLICATION") AND PROVISION OF NECESSARY SUPPORTING DOCUMENTATION. Schedule H, Part V, Section B, Line 22 Charges to FAP eligible individuals DEPENDING ON A PATIENT'S FINANCIAL SITUATION, FAP-ELIGIBLE PATIENTS WERE CHARGED AMOUNTS RANGING FROM 0% OF BILLED CHARGES UP TO THE APPLICABLE AGB PERCENTAGE OF BILLED CHARGES, WHICH WAS NOT MORE THAN THE AGB. IN FY25, DFCI DETERMINED AGB ON AN ANNUAL BASIS USING THE "LOOK-BACK METHOD," DESCRIBED UNDER TREASURY REGULATION SECTION 1.501(R)-5(B)(1). SPECIFICALLY, DFCI'S ANNUAL AGB PERCENTAGE WAS EQUAL TO SUM OF ALL GROSS CHARGES DURING THE PRIOR FISCAL YEAR DIVIDED BY CLAIMS PAID IN CONNECTION WITH THOSE CHARGES. FOR PURPOSES OF THE AGB CALCULATION, CLAIMS PAID INCLUDED CLAIMS FOR EMERGENCY AND MEDICALLY NECESSARY CARE PAID BY BOTH MEDICARE FEE-FOR-SERVICE AND ALL PRIVATE HEALTH INSURERS AS PRIMARY PAYERS, TOGETHER WITH ANY ASSOCIATED PORTIONS OF THESE CLAIMS PAID BY MEDICARE BENEFICIARIES OR INSURED INDIVIDUALS IN THE FORM OF CO-PAYMENTS, CO-INSURANCE OR DEDUCTIBLES. Schedule H, Part I, Line 6a Community benefit report prepared by related organization DANA-FARBER CANCER INSTITUTE ("DFCI") Schedule H, Part I, Line 7 Bad Debt Expense excluded from financial assistance calculation 1646424 Schedule H, Part III, Line 4 Bad debt expense - financial statement footnote CONSISTENT WITH THE INSTITUTE'S MISSION, CARE IS PROVIDED TO PATIENTS REGARDLESS OF THEIR ABILITY TO PAY. THE INSTITUTE HAS DETERMINED IT HAS PROVIDED IMPLICIT PRICE CONCESSIONS TO UNINSURED PATIENTS AND PATIENTS WITH OTHER UNINSURED BALANCES (E.G. COPAYS AND DEDUCTIBLES). THE IMPLICIT PRICE CONCESSIONS INCLUDED IN ESTIMATING THE TRANSACTION PRICE REPRESENT THE DIFFERENCE BETWEEN AMOUNTS BILLED TO PATIENTS AND THE AMOUNTS THE INSTITUTE EXPECTS TO COLLECT BASED ON ITS COLLECTION HISTORY WITH THOSE PATIENTS. PATIENTS WHO MEET THE INSTITUTE'S CRITERIA FOR CHARITY CARE ARE PROVIDED CARE WITHOUT CHARGE OR AT AMOUNTS LESS THAN ESTABLISHED RATES. THE INSTIUTE HAS DETERMINED THAT IT HAS PROVIDED SUFFICIENT IMPLICIT PRICE CONCESSIONS FOR THESE ACCOUNTS. PRICE CONCESSIONS, INCLUDING CHARITY CARE, ARE NOT REPORTED AS REVENUE. Schedule H, Part III, Line 8 Community benefit & methodology for determining medicare costs THE MEDICARE COST ON LINE 6 COMES FROM THE MEDICARE COST REPORT AND IS BASED ON MEDICARE'S COST FINDING PRINCIPLES AND METHODOLOGIES. WE STRONGLY BELIEVE THAT THE ENTIRE AMOUNT OF THE SHORTFALL OF $85,990,129 SHOULD BE TREATED AS A COMMUNITY BENEFIT AS THIS REPRESENTS THE INSTITUTE'S COMMITMENT TO THE ELDERLY AND DISABLED COMMUNITY BY PROVIDING SERVICES THAT ARE NOT REIMBURSED. Schedule H, Part III, Line 9b Collection practices for patients eligible for financial assistance WITHIN DFCI'S CREDIT AND COLLECTIONS POLICY THERE ARE PROVISIONS THAT DESCRIBE COLLECTION PRACTICES TO BE FOLLOWED FOR PATIENTS WHO ARE KNOWN TO QUALIFY FOR CHARITY CARE OR FINANCIAL ASSISTANCE IN ACCORDANCE WITH FEDERAL AND MASSACHUSETTS LAW. Schedule H, Part V, Section B, Line 16a FAP website - DANA-FARBER CANCER INSTITUTE, INC.: Line 16a URL: https://www.dana-farber.org/patient-family/support-services/patient-financial-assistance; Schedule H, Part V, Section B, Line 16b FAP Application website - DANA-FARBER CANCER INSTITUTE, INC.: Line 16b URL: https://www.dana-farber.org/patient-family/support-services/patient-financial-assistance; Schedule H, Part V, Section B, Line 16c FAP plain language summary website - DANA-FARBER CANCER INSTITUTE, INC.: Line 16c URL: https://www.dana-farber.org/patient-family/support-services/patient-financial-assistance; Schedule H, Part VI, Line 2 Needs assessment DANA-FARBER CANCER INSTITUTE CONTINUOUSLY ASSESSES THE COMMUNITY NEEDS THROUGH OUR PARTICIPATION IN COMMUNITY COALITIONS, TASK FORCES, WORKING GROUPS AND DIRECT COMMUNICATION WITH THE COMMUNITY RESIDENTS THAT SERVE ON OUR EXTERNAL ADVISORY COMMITTEE AND ON OUR PATIENT AND FAMILY ADVISORY BOARD. A FULL DESCRIPTION OF OUR COMMUNITY ENGAGEMENT PROCESS CAN BE FOUND ON OUR WEBSITE BOTH IN THE COMMUNITY HEALTH NEEDS ASSESSMENT REPORT AND IN THE COMMUNITY HEALTH IMPLEMENTATION PLAN. Schedule H, Part VI, Line 3 Patient education of eligibility for assistance DFCI IS COMMITTED TO OFFERING FINANCIAL ASSISTANCE TO ELIGIBLE PATIENTS WHO DO NOT HAVE THE ABILITY TO PAY FOR THEIR MEDICAL SERVICES IN WHOLE OR IN PART. IN ORDER TO ACCOMPLISH THIS CHARITABLE GOAL, DFCI WIDELY PUBLICIZES ITS PATIENT FINANCIAL ASSISTANCE (PFA) POLICY WITHIN ITS FACILITIES, IN DIRECT COMMUNICATIONS WITH PATIENTS AND IN THE COMMUNITIES THAT IT SERVES, PARTICULARLY IN THE COMMUNITIES WITH THE GREATEST UNMET HEALTH NEEDS. THE PFA POLICY, A PLAIN LANGUAGE PFA SUMMARY AND THE PFA APPLICATION ARE POSTED ON DFCI'S WEBSITE IN ENGLISH AND SPANISH. IN ADDITION, INFORMATION ABOUT THE PFA IS PROVIDED TO ALL PATIENTS AT REGISTRATION AND/OR ADMISSION, AND IS AVAILABLE UPON REQUEST, WITHOUT CHARGE, THROUGH A DFCI FINANCIAL COUNSELOR, CUSTOMER SERVICE REPRESENTATIVE, OR BY MAIL. FOLLOWING CARE, ALL BILLING STATEMENTS SENT TO A PATIENT INDICATE HOW THE PATIENT CAN OBTAIN INFORMATION ABOUT THE PFA POLICY. IN COLLABORATION WITH DFCI'S COMMUNITY PARTNERS, INFORMATION ABOUT THE FAP IS SHARED WITH RESIDENTS OF DFCI'S PRIORITY NEIGHBORHOODS. EFFORTS TO NOTIFY COMMUNITY MEMBERS MOST LIKELY TO REQUIRE ASSISTANCE INCLUDE DISTRIBUTING PLAIN LANGUAGE SUMMARIES OF THIS POLICY TO LOCAL COMMUNITY HEALTH CENTERS AND OTHER NON-PROFIT ORGANIZATIONS. Schedule H, Part VI, Line 4 Community information DANA-FARBER SERVES THE COMMUNITY OF EASTERN MASSACHUSETTS, INCLUDING THE COMMUNITIES SURROUNDING ITS PRIMARY LOCATION IN BOSTON AND ITS SATELLITE LOCATIONS IN MILFORD, MASSACHUSETTS, WEYMOUTH, MASSACHUSETTS, BRIGHTON, MASSACHUSETTS, NEWTON, MASSACHUSETTS, METHUEN, MASSACHUSETTS, FOXBOROUGH, MASSACHUSETTS AND LONDONDERRY, NEW HAMPSHIRE. DANA-FARBER'S COMMUNITY INCLUDES ADULTS AND CHILDREN WITH CANCER OR AT RISK OF DEVELOPING CANCER, AND THEIR FAMILIES. Dana-Farber focuses its community outreach efforts on its priority Boston neighborhoods of Dorchester, East Boston, Jamaica Plain, Mattapan, Mission Hill, and Roxbury. The median incomes of Dana-Farber's priority communities are generally much lower than Boston overall, with Roxbury at a median income of $47,921, Dorchester at $58,681, and Mattapan at $67,206. Residents in Dana-Farber's priority neighborhoods appear to experience higher rates of poverty than Boston overall. Schedule H, Part VI, Line 5 Promotion of community health Dana-Farber's 2025-2028 Community Health Needs Assessment and Implementation Plan provide a robust description of our comprehensive cancer control programs and services. The report also provides a summary of accomplishments from our last needs assessment and sets forth our commitment to addressing the new opportunities to reduce the cancer burden in medically underserved communities in Boston. The reports can be found using the following links: COMMUNITY HEALTH NEEDS ASSESSMENT - https://www.dana-farber.org/community-health/community-health-needs-assessment IMPLEMENTATION PLAN -https://www.dana-farber.org/community-health/community-health-needs-assessment Schedule H, Part VI, Line 7 State filing of community benefit report MA true CITY OF BOSTON City Hall Plaza Boston MA 02114 046001380 115 1692833 Community Support HARVARD UNIVERSITY 60 Oxford St Cambridge MA 02138 042103580 501(c)(3) 1493414 Cancer Research and Development ALTERNATIVES FOR COMMUNITY 2181 WASHINGTON STREET SUITE 301 ROXBURY MA 02119 043228509 501(c)(3) 199998 Community Support FamilyAid Boston 3815 Washington St Boston MA 02130 042105756 501(c)(3) 184236 Community Support BOSTON ATHLETIC ASSOCIATION 40 TRINITY PLACE 4TH FLOOR BOSTON MA 02116 046111707 501(c)(3) 160000 Community Support Project Bread 145 Border Street East Boston MA 02128 042931195 501(c)(3) 100000 Community Support GREENROOTS INC 90 EVERETT AVE 3RD FLOOR SUITE 10 CHELSEA MA 021502317 812718273 501(c)(3) 100000 Community Support FRIENDS OF DANA FARBER 450 Brookline Ave Boston MA 02215 371613621 501(c)(3) 50000 Cancer Research and Development Conference Of Boston Teaching Hospitals 11 Beacon ST Suite 625 BOSTON MA 01208 263583138 501(c)(6) 50000 Community Support HEALTH EQUITY COMPACT INC 40 COURT ST FL 10 BOSTON MA 021082212 990943875 501(c)(3) 50000 Community Support AMERICAN CANCER SOCIETY 250 Williams St Atlanta GA 30303 131788491 501(c)(3) 30000 Cancer Research and Development BLOOD CANCER UNITED INC PO BOX 22470 NEW YORK NY 10087 135644916 501(c)(3) 25000 Cancer Research and Development ALLSTON BRIGHTON COMMUNITY DEVELOPMENT 18R SHEPARD STREET SUITE 100 BRIGHTON MA 02135 042716278 501(c)(3) 21000 Community Support WHITTIER STREET HEALTH CENTER 1125 Tremont Street Roxbury MA 02120 042619517 501(c)(3) 20000 Community Support JOE ANDRUZZI FOUNDATION INC 49 PLAIN ST NORTH ATTLEBORO MA 02760 252017043 501(c)(3) 20000 Cancer Research and Development THE DINNER GROUP INC 3096 WASHINGTON STREET CANTON MA 02021 842261255 509(a)(2) 20000 Community Support THE BREAST CANCER RESEARCH FOUNDATION 60 EAST 56TH STREET 8TH FLOOR NEW YORK NY 10022 133727250 501(c)(3) 15000 Cancer Research and Development PANCREATIC CANCER ACTION NETWORK 1500 ROSECRANS AVENUE SUITE 3200 EL SEGUNDO CA 90245 330841281 501(c)(3) 15000 Cancer Research and Development HEALTH CARE FOR ALL 30 WINTER STREET BOSTON MA 02108 043071598 501(c)(3) 12000 Community Support COMMUNITY SERVINGS 179 Armory Street Jamaica Plain MA 02130 223154028 501(c)(3) 10000 Community Support MASSACHUSETTS LEAGUE OF COMMUNITY 40 Court Street 10Th Floor Boston MA 02108 042507409 501(c)(3) 10000 Community Support SUSAN G KOMEN BREAST CANCER FOUNDATION 5005 Lbj Suite 370 Dallas TX 75380 751835298 501(c)(3) 10000 Cancer Research and Development UNION CAPITAL BOSTON INC 1542 COLUMBUS AVENUE ROXBURY MA 02119 471136081 501(c)(3) 10000 Community Support CRISTO REY BOSTON HIGH SCHOOL INC 100 SAVIN HILL AVENUE BOSTON MA 02125 562438544 501(c)(3) 10000 Community Support UNITED NEGRO COLLEGE FUND INC 1805 7TH STREET NW WASHINGTON DC 20001 131624241 501(c)(3) 10000 Community Support AMERICAN INDIAN CANCER FOUNDATION 34 13TH AVE NE SUITE 112 MINNEAPOLIS MN 55413 270300026 501(c)(3) 10000 Cancer Research and Development JUNIOR ACHIEVEMENT OF GREATER BOSTON IN 80 CITY SQ BOSTON MA 021293742 042127020 501(c)(3) 10000 Community Support NEW ENGLAND COUNCIL INC 98 NORTH WASHINGTON STREET SUITE 303 BOSTON MA 02114 041661090 501(c)(6) 10000 Community Support RESEARCHAMERICA 241 18TH ST S SUITE 501 ARLINGTON VA 22202 521609875 501(c)(3) 10000 Cancer Research and Development YOUTH ENRICHMENT SERVICES 412 MASSACHUSETTS AVENUE BOSTON MA 02118 042509466 501(c)(3) 10000 Community Support BOYS & GIRLS CLUB OF BOSTON 200 High Street Suite 3B BOSTON MA 02110 042103922 501(c)(3) 7500 Community Support NATIONAL MARROW DONOR PROGRAM 500 N 5th St MINNEAPOLIS MN 55401 840865803 501(c)(3) 7500 Cancer Research and Development NEW ENGLAND EMPLOYEE BENEFITS COUNCIL 561 VIRGINIA RD SUITE 217 CONCORD MA 01742 042725284 501(c)(3) 7000 Community Support SOCIEDAD LATINA INC 1530 TREMONT STREET ROXBURY MA 02120 042678255 501(c)(3) 5500 Community Support 32 2 Patient Assistance 810 913492 Miscellaneous Patient Assistance 3547 2765629 FMV Asst Living & Travel Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS ALL GRANTS AND DONATIONS TO DOMESTIC ORGANIZATIONS WERE GIVEN TO 501(C)(3) ORGANIZATIONS TO FULFILL THEIR MISSIONS, OR GOVERNMENT ENTITIES. ALL GRANT FUNDS TO INDIVIDUALS WERE PROVIDED BASED ON EITHER (AND ONLY) 1) MEANS-TESTED FINANCIAL NEED, OR 2) CLINICALLY DETERMINED IMPROVEMENT TO QUALITY-OF-LIFE. X true false X X X X X false true false false false false false true false Benjamin Ebert MD PhD TRUSTEE, PRESIDENT, & CEO (AS OF 10/1/24) 427658 0 0 0 40433 0 48495 0 14929 0 531515 0 0 0 John O Chesley ESQ Former Officer 416000 0 74 0 1458 0 0 0 172 0 417704 0 0 0 Bruce Johnson MD Former 67846 0 116794 0 106027 0 10772 0 31314 0 332753 0 0 0 William Hahn MD PHD COO & EVP 992361 0 372372 0 88539 0 48495 0 3598 0 1505365 0 0 0 Michael L Reney CFO & Assistant Treasurer 832796 0 316316 0 68640 0 48495 0 3676 0 1269923 0 0 0 Jennifer Willcox ESQ Asst Secretary & General Counsel 623292 0 165466 0 83551 0 48495 0 37234 0 958038 0 0 0 Sylvia A Bartel RPh MHP SR. VP of Pharmacy & CPO 333531 0 32203 0 8423 0 48495 0 40140 0 462792 0 0 0 Craig A Bunnell MD MPH MBA Chief Medical Officer 781580 0 215329 0 69774 0 48496 0 41367 0 1156546 0 0 0 Melany Duval SVP & Chief Philanthropy Officer 830831 0 257160 0 66119 0 48404 0 22696 0 1225210 0 0 0 Wendy Gettleman VP of Facilities Management & Real Estate 363183 0 34685 0 2642 0 47976 0 43957 0 492443 0 0 0 Kevin Haigis PHD Chief Scientific Officer 556399 0 104499 0 30908 0 48495 0 3555 0 743856 0 0 0 Naomi Lenane SVP INFORMATION SERVICES CIO 142430 0 26333 0 575 0 15563 0 13749 0 198650 0 0 0 Patrick McCormick SVP HOSPITAL TRANSFORMATION 195659 0 125000 0 73510 0 0 0 10879 0 405048 0 0 0 Jeffrey Meyerhardt MD MPH Chief Clinical Research Officer 588372 0 128236 0 36179 0 48495 0 43564 0 844846 0 0 0 Maria Megdal SVP Chief Administrative Officer 436433 0 142317 0 70880 0 48495 0 58912 0 757037 0 0 0 Barrett J Rollins MD PHD Sr. Advisor to President & CEO 530411 0 0 0 34935 0 48495 0 11867 0 625708 0 0 0 Scott Armstrong MD PHD Chair of Pediatric Oncology 653064 0 123907 0 66355 0 48495 0 36047 0 927868 0 0 0 Michael Constantine MD Milford Med Dir-Hematology/Oncology 722581 0 52849 0 56220 0 48495 0 44624 0 924769 0 0 0 George D Demetri MD PROFESSOR 624541 0 107762 0 49161 0 48495 0 23521 0 853480 0 0 0 Laurie H Glimcher MD President & CEO Emerita 1461748 0 695680 0 155591 0 347058 0 19573 0 2679650 0 0 0 Robert Soiffer MD Chief Clinical Program Officer 655296 0 160997 0 65893 0 48495 0 23239 0 953920 0 0 0 Schedule J, Part I, Line 1a Tax indemnification and gross-up payments FOR THE FOLLOWING, BENEFITS REPORTED IN PART VII INCLUDES GROSS-UP PAYMENTS FOR AN EMPLOYEE RECOGNITION PROGRAM AWARD: 5 KEY EMPLOYEES 1 OFFICER 1 FORMER OFFICER Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan THE FOLLOWING INDIVIDUALS PARTICIPATE IN 457(F) PLANS ESTABLISHED BY DFCI; TAXABLE AMOUNTS ARE INCLUDED IN REPORTABLE COMPENSATION IN SCHEDULE J, PART II, COLUMN (B)(III): OTHER REPORTABLE COMPENSATION INCLUDES LOAN FORGIVENESS AND CURRENT YEAR VESTING AMOUNTS IN DANA-FARBER INSTITUTE'S SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. Laurie Glimcher, MD - $140,759 Bruce Johnson, MD - $103,372 William Hahn, MD, Ph.D - $81,145 Jennifer Willcox, ESQ - $77,848 Maria Megdal - $67,043 Melany Duval - $61,217 Michael Reney - $61,116 Craig A. Bunnell, MD - $56,650 Michael Constantine, MD - $48,696 Scott Armstrong, MD - $39,616 Robert Soiffer, MD - $39,344 George D. Demetri, MD - $35,537 Jeffrey Meyerhardt, MD, Ph.D - $31,795 Kevin Haigis, Ph.D - $26,656 Barrett J. Rollins, MD, Ph.D - $23,349 Benjamin Ebert, MD, Ph.D - $11,197 Sylvia Bartel, RPh, MHP - $245 Schedule J, Part I, Line 7 Non-fixed payments DURING THE YEAR, THE CEO, COO, CFO, GENERAL COUNSEL, CERTAIN KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES WERE ELIGIBLE TO RECEIVE AN INCENTIVE PAYMENT, A PORTION OF WHICH HAS A NON-FIXED PAYMENT PAYABLE AT THE DISCRETION OF THE CEO AND IN THE CASE OF THE CEO, THE BOARD OF TRUSTEES. THE MAXIMUM NON-FIXED PORTION OF THESE INCENTIVE PAYMENTS IS BETWEEN 8% (CEO - 40% MAX, OF THAT 32% TEAM, 8% INDIVIDUAL) AND 4% (SVP - 20% MAX, OF THAT 16% TEAM AND 4% INDIVIDUAL; VP - 10% MAX, OF THAT 6% TEAM AND 4% INDIVIDUAL; AND (EVP - 30% MAX, OF THAT 24% TEAM AND 6% INDIVIDUAL). A MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 2025-08-04 92500000 THE BOND ISSUE WAS USED TO REFUND SERIES L-1 BONDS ISSUED ON 8/3/2015 false false false B MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 05758XNZ0 2016-06-23 281786480 (SEE STATEMENT) false false false C MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 57584YVC0 2019-09-03 60255238 THE BOND ISSUE WAS USED TO REFUND SERIES K BONDS ISSUED ON 5/22/2008. false false false D MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 2021-07-28 57500000 THE BOND ISSUE WAS USED TO REFUND SERIES L-2A BONDS ISSUED ON 7/2/2012. false false false A 92500000 92500000 2025 true false true true B 282914006 1127526 2486701 279299779 2019 false false true true C 60255238 1163957 59091281 2019 true false true true D 57500000 57500000 2021 true false true true A false false true true true true 0.0 0.0 0.0 false false 0 false true B false false false false true true 0.0 0.0 0.0 false false 0 false true C false false true true true true 0.0 0.0 0.0 false false 0 false true D false false true true true true 0.0 0.0 0.0 false false 0 false true A false false true false true true MORGAN STANLEY CAPITAL SERVICES INC 39.8 false false false 0 false false true B false false false true false false 0 false false false 0 false false true C false false false true false false 0 false false false 0 false false true D false false true false true true MORGAN STANLEY CAPITAL SERVICES INC 39.8 false false false 0 false false true A true B true C true D true Schedule K, Part I, Column (f) B (F) DESCRIPTION OF PURPOSE THE BOND ISSUE WAS USED TO PARTIALLY COVER THE ACQUISITION AND FIT-OUT OF RESEARCH SPACE AND VIVARIUM AT THE LONGWOOD CENTER; TO PARTIALLY COVER THE REPLACEMENT OF HVAC SYSTEM AT THE SMITH BUILDING; TO COVER THE RELOCATION TO, RECONSTRUCTION AND EQUIPPING OF THE INSTITUTE'S CELL MANIPULATION CORE FACILITY; AND TO COVER THE COSTS OF BOND ISSUANCE AND INTEREST DURING THE CONSTRUCTION PERIOD AS WELL AS OTHER CAPITAL PROJECTS. Schedule K, Part II (PROCEEDS) B 3 THE TOTAL PROCEEDS OF $282,914,006 INCLUDE INVESTMENT EARNINGS IN THE AMOUNT OF $1,127,526. Schedule K, Part IV SCHEDULE K, PART IV (ARBITRAGE) A 2(c) This issuance was refunded in 2025 and had no invested assets and qualifies for 6-month spending exception. D 2(b) This issuance was refunded in 2021 and had no invested assets and qualifies for 6-month spending exception. E 2(b) This issuance was refunded in 2021 and had no invested assets and qualifies for 6-month spending exception. Schedule K, Part IV, Line 2c COLUMN B Issuer name: MASSACHUSETTS DEVELOPMENT FINANCE AGENCY The calculation for computing no rebate due was performed on 11/01/2020 Schedule K, Part IV, Line 2c COLUMN C Issuer name: MASSACHUSETTS DEVELOPMENT FINANCE AGENCY The calculation for computing no rebate due was performed on 11/01/2020 A MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 2021-07-28 35000000 THE BOND ISSUE WAS USED TO REFUND SERIES L-2B BONDS ISSUED ON 7/2/2012. false false false A 35000000 35000000 2021 true false true true A false false true true true true 0.0 0.0 0.0 false false 0 false true A false false true false true true MORGAN STANLEY CAPITAL SERVICES INC 39.8 false false false 0 false false true A true Duval Melany Employee Housing Loan X 150000 48750 false true true Ebert Benjamin Employee Tuition Assistance X 210482 189566 false true true Hahn William Employee Tuition Assistance X 128074 120282 false true true Haigis Kevin Employee Housing Loan X 100000 45834 false true true Haigis Kevin Employee Tuition Assistance X 46482 43202 false true true McCormick Patrick Employee Housing Loan X 300000 291667 false true true Willcox Jennifer Employee Tuition Assistance X 226121 211717 false true true 951018 X 1650000 Market value 42 49695 Market value 257 28187072 Market value 11 200497 Market value X EVENT TICKETS 7 970667 Market value X MISCELLANEOUS 2 81484 Market value false true true Schedule M, Part I COLUMN (B) DANA-FARBER CANCER INSTITUTE, INC. (DFCI) IS REPORTING THE NUMBER OF CONTRIBUTIONS RECEIVED. Schedule M, Part I, Line 32b Third parties used to solicit, process, or sell noncash contributions DFCI HAS AN ARRANGEMENT WITH ANOTHER CHARITY PURSUANT TO WHICH THE OTHER CHARITY ACCEPTS CERTAIN NONCASH DONATIONS FOR THE BENEFIT OF DANA-FARBER. PROCEEDS FROM THE SALE OF NONCASH DONATIONS ARE DIRECTED TO A DESIGNATED FUND FOR THE BENEFIT OF DANA-FARBER. IN ADDITION, DANA-FARBER HAS AN ARRANGEMENT WITH ANOTHER CHARITY PURSUANT TO WHICH THE OTHER CHARITY PROCESSES VEHICLE DONATIONS FOR THE BENEFIT OF DANA-FARBER. PROCEEDS FROM THE SALE OF DONATED VEHICLES ARE DIRECTED TO DANA-FARBER. Schedule M, Part I, Line 33 Noncash contribution amounts not reported DFCI RECEIVED DONATIONS OF ART, BOOKS, AND OTHER GOODS THAT IT DISPLAYS IN ITS PROPERTIES. THESE GOODS HAVE VALUES THAT ARE EITHER NOMINAL OR ARE NOT READILY DETERMINABLE AND ARE, THEREFORE, NOT INCLUDED AS REVENUE. Form 990, Part I, Line 1 Organization's mission THE MISSION OF DANA-FARBER CANCER INSTITUTE (DFCI) IS TO PROVIDE EXPERT, COMPASSIONATE, AND EQUITABLE CARE TO CHILDREN, ADULTS, AND THEIR FAMILIES, WHILE ADVANCING THE UNDERSTANDING, DIAGNOSIS, TREATMENT, CURE, AND PREVENTION OF CANCER AND RELATED DISEASES. WE TRAIN NEW GENERATIONS OF CLINICIANS AND SCIENTISTS, DISSEMINATE INNOVATIVE PATIENT THERAPIES AND SCIENTIFIC DISCOVERIES AROUND THE WORLD, AND REDUCE THE IMPACT OF CANCER, WHILE AT ALL TIMES MAINTAINING A FOCUS ON THOSE COMMUNITIES THAT HAVE BEEN HISTORICALLY MARGINALIZED. Form 990, Part III, Line 1 Organization's mission THE MISSION OF DFCI IS TO PROVIDE EXPERT, COMPASSIONATE, AND EQUITABLE CARE TO CHILDREN, ADULTS, AND THEIR FAMILIES, WHILE ADVANCING THE UNDERSTANDING, DIAGNOSIS, TREATMENT, CURE, AND PREVENTION OF CANCER AND RELATED DISEASES. WE TRAIN NEW GENERATIONS OF CLINICIANS AND SCIENTISTS, DISSEMINATE INNOVATIVE PATIENT THERAPIES AND SCIENTIFIC DISCOVERIES AROUND THE WORLD, AND REDUCE THE IMPACT OF CANCER, WHILE AT ALL TIMES MAINTAINING A FOCUS ON THOSE COMMUNITIES THAT HAVE BEEN HISTORICALLY MARGINALIZED. Form 990, Part III, Line 4a Program Service Accomplishments CLINICAL CARE AS ONE OF THE LEADING CANCER CENTERS IN THE WORLD, DANA-FARBER CANCER INSTITUTE PROVIDES COMPASSIONATE, COMPREHENSIVE, AND PERSONALIZED CARE TO ADULTS AND CHILDREN WITH CANCER, BLOOD DISORDERS, AND RELATED DISEASES. IN FISCAL YEAR 2025, OUR EXPERT CLINICIANS AND CAREGIVERS AT OUR SPECIALIZED TREATMENT CENTERS WORKED TOGETHER TO DELIVER THE LATEST THERAPIES TO OUR PATIENTS THROUGH 1,295 INPATIENT ADMISSIONS, 417,867 OUTPATIENT DOCTOR VISITS, AND 242,140 INFUSION TREATMENTS. SINCE ITS FOUNDING IN 1947 BY SIDNEY FARBER, MD, DANA-FARBER HAS FOLLOWED HIS VISION FOR A CANCER CENTER THAT IS JUST AS DEDICATED TO DISCOVERIES IN CANCER RESEARCH AS IT IS TO DELIVERING EXPERT, COMPASSIONATE CARE. OUR INSTITUTE IS A FOUNDING MEMBER OF DANA-FARBER/HARVARD CANCER CENTER AND ONE OF 57 NCI-DESIGNATED COMPREHENSIVE CANCER CENTERS IN THE U.S. WE ARE THE ONLY HOSPITAL RANKED IN THE TOP THREE NATIONALLY BY U.S. NEWS AND WORLD REPORT IN BOTH ADULT AND PEDIATRIC CANCER CARE. IN 2025, WE OFFERED MORE THAN 1,200 CLINICAL TRIALS Form 990, Part III, Line 4b Program Service Accomplishments RESEARCH Scientific work at Dana-Farber is based on the premise that basic and clinical investigation are complementary and reinforcing activities. To encourage this cross-pollination of ideas, the institute has developed an organizational framework that fosters collaborations among investigators from different disciplines. The result is an intense scientific impact on a group of diseases that continue to represent one of humanity's greatest health challenges. Some recent advances include: Belzutifan approved by US Food and Drug Administration (FDA) for kidney cancer: in a large phase 3 multicenter clinical trial, patients with metastatic clear cell renal cell carcinoma who received belzutifan had better survival outcomes than those who received standard therapy. Cabozantinib approved by us FDA for neuroendocrine tumors of the pancreas or elsewhere: in a phase 3 clinical trial, patients with previously treated, advanced disease who received cabozantinib had better survival outcomes than those who received a placebo. Dordaviprone was granted accelerated approval by us FDA for patients with recurrent rare fatal brain cancer: in a phase 2 clinical trial, dordaviprone, an oral, first in class targeted medicine, was well tolerated by patients with recurrent h3 k27m-mutant diffuse midline glioma and provided a durable response for some patients. Pembrolizumab approved by us FDA as up-front treatment for head and neck cancer: in a pivotal phase 3 trial, patients who received pembrolizumab before, during, and after steadard care had better survival outcomes than those who received standard care alone. Ruvemenib approved by us FDA for relapsed or refractory acute myeloid leukemia with common mutations: revumenib is a first-in-class oral menin inhibitor that was approved for the treatment of patients with kmt2a translocations in 2024. The 2025 approval was based on results of a phase 2 clinical trial for patients with npm1 mutations, giving up to 40% of patients with AML access to this medicine. Sunvozertinib approved by us FDA for egfr-mutated non-small cell lung cancer: in a phase 2 clinical trial, sunvozertinib showed positive results for patients with previously treated advanced non-small cell lung cancer with certain EGFR mutations. Antibody-drug conjugate (ADC) shows promise as first-line therapy for patients with advanced triple negative breast cancer who are not eligible for immunotherapy: a phase 3 clinical trial reported early results suggesting that patients who received sacituzumab govitecan had improved progression-free survival compared to patients receiving standard chemotherapy. Adc combination shows promise for metastatic her2-positive breast cancer: a phase 3 trial reported improved progression-free survival for patients receiving a combination of trastuzumab deruxtecan plus pertuzumab compared to current standard first line therapy. Ras inhibitor shows promise in advanced pancreatic cancer: early results of a phase 1/2 clinical trial supported the initiation of a phase 3 study comparing daraxonrasib to second line chemotherapy for patients with advanced pancreatic cancer. Personalized cancer vaccines continue to be improved and tested: early phase clinical trials reported promising results in kidney cancer and in melanoma. Natural killer (NK) cell therapies continue to be designed and tested: a new clinical trial testing NK cell therapies has begun in ovarian cancer. Direct cyclin inhibitors: direct cyclin inhibitors are a new class of medicine that disables a quality control checkpoint in the cell cycle. Laboratory evidence supported the launch of a nationwide phase 1 clinical trial of a first-in-class direct cyclin inhibitor for patients with small cell lung cancer, triple negative breast cancer and other cancers. Weight-loss intervention validated: clinical trials can now proceed to determine if weight loss through use of the validated intervention can help reduce the risk of breast cancer recurrence. Exercise and diet influence survival: clinical studies reported that after treatment for colorectal cancer, exercise and anti-inflammatory diets can improve survival. Acute leukemia diagnostic: a new diagnostic tool for acute leukemia could significantly improve patient care by allowing faster and more precise treatment decisions. Multiple myeloma blood test: a novel blood test for multiple myeloma enables diagnosis of multiple myeloma and its precursors using a blood test, offering an alternative to traditional bone marrow biopsy. Form 990, Part III, Line 4c Program service accomplishments COMMUNITY HEALTH The role of Dana-Farber's Community Health office is to support the Institute's goal to reduce cancer risk among medically underserved populations. We work with city and state health departments, community partners, and Boston-based coalitions to assess and monitor the needs of local residents with respect to cancer control. In collaboration with staff throughout Dana-Farber, we serve as a bridge with community organizations and establish evidence-based and sustainable outreach programs. We are on the front lines of supporting and collaborating on programs designed to eliminate disparities in breast, colon, and skin cancer; educate diverse populations about tobacco cessation, human papillomavirus (HPV) prevention and screening; and strengthen the support system for medically underserved populations. In short, we are committed to making Dana-Farber's care and research findings more accessible to everyone within and outside its walls. FY25 programmatic highlights are as follows: Dana-Farber's mammography services provided 2,836 mammograms on the van and at the mammography suite at Whittier Street Health Center in Roxbury. Dana-Farber's Sun Safety Program provided 16 in-person sun safety screening events with added health and safety measures. 860 participants were screened by a dermatologist and 123 people were referred for follow-up appointments. 52 participants were referred for a biopsy. Dana-Farber's Tobacco Treatment program received 28 referrals and provided 35 individual tobacco cessation counseling sessions to 13 patients. 9 participants were able to reduce their total number of cigarettes smoked per day, and 4 of these reported being able to quit completely. The Tobacco Treatment program continued to provide financial incentives for participants enrolled in the program. Stop and Shop gift cards were provided after counseling sessions to encourage individuals to reduce their tobacco usage and quit smoking. Continued to partner with the Breast Oncology Department in managing AssessYourRisk, a digital tool to help people of all ages better understand and manage their risk of breast and ovarian cancer. The survey tool was completed by over 10,000 users in FY25. Implemented and evaluated the fourth and final year of Dana-Farber's multi-year Systems Level Funding, awarded to three non-profit organizations in Greater Boston to address air quality, environmental justice, and child homelessness. Successes from the fourth year include advancing air quality legislation, launching community-owned data tools, strengthening cross-sector partnerships, and deepening resident and youth leadership - building momentum for continued policy, systems, and environmental (PSE) change beyond the grant-funded period. The Education and Outreach team held 65 events in 5 languages (English, Cantonese, Haitian-Creole, Mandarin, and Spanish), reaching a total of 4,868 participants. These events included cancer education sessions on topics including General Cancer Prevention & Resources, HPV-Related Cancer, Breast Cancer, and Colorectal Cancer, and Prostate Cancer, as well as community events including tabling at health fairs, farmers markets, and cultural celebrations such as Lunar New Year and Pride for the People, where we provide tailored education materials and speak to community members in our priority populations about cancer prevention. The Education and Outreach team expanded outreach in bilingual media, specifically for Spanish speaking and Chinese populations. In FY25, we published 44 posts in Simplified and Traditional Chinese on WeChat, a social media platform popular among Chinese populations. We also participated in 4 interviews on Spanish media platforms (Telemundo, Univision, La Mega Radio, Orale con Veronica) focused on breast and colorectal cancer screening. Lastly, we published 4 articles in Spanish in El Mundo newspaper. From late 2024 through early 2025, Dana-Farber's Community Health Office, in collaboration with the Community Benefits External/Determination of Need (DoN) Advisory Committee, conducted a series of community information sessions to solicit public input related to planning for Dana-Farber's proposed inpatient adult cancer hospital. Form 990, Part VI, Line 2 Family/business relationships amongst interested persons ANDREW JANOWER AND MICHAEL EISENSON - Business relationship, JOSH BEKENSTEIN, ANDREW KAPLAN, AND NANCY LOTANE - Business relationship, RICHARD LUBIN, CHRISTOPHER HADLEY, AND JANE BROCK-WILSON - Business relationship, SUSHIL TULI AND PETER PALANDJIAN - Business relationship, BRIAN KNEZ AND JESSICA KNEZ DULAC - Family relationship Form 990, Part VI, Line 11b Review of form 990 by governing body THE DFCI'S TAX DEPARTMENT PROVIDES ALL FINANCIAL ANALYSIS AND OTHER INFORMATION TO BE INCLUDED ON THE TAX RETURN TO ITS EXTERNAL TAX PREPARER, ERNST & YOUNG LLP, WHICH PREPARES THE DRAFT RETURN. THE DRAFT RETURN IS THEN REVIEWED BY THE DFCI'S TAX MANAGER, AS WELL AS THE DFCI'S OFFICE OF GENERAL COUNSEL AND SENIOR MANAGEMENT, BEFORE IT IS SUBMITTED FOR AUDIT COMMITTEE REVIEW. AFTER THE AUDIT COMMITTEE REVIEWS THE TAX RETURN, AN ELECTRONIC MESSAGE IS SENT TO ALL GOVERNING BOARD MEMBERS WITH A SECURE LINK TO THE TAX RETURN. THE BOARD HAS THE OPPORTUNITY TO REVIEW THE RETURN AND BRING ANY ISSUES TO THE ATTENTION OF THE APPROPRIATE EXECUTIVE MANAGEMENT INDIVIDUALS. A FINAL VERSION OF THE FORM IS APPROVED BY THE CFO AND FILED ELECTRONICALLY BY ERNST & YOUNG LLP WITH THE IRS. Form 990, Part VI, Line 12c Conflict of interest policy DFCI MONITORS AND ENFORCES COMPLIANCE WITH THE DFCI CONFLICT OF INTEREST AND CONFIDENTIALITY POLICY FOR BOARD OFFICERS, TRUSTEES, AND KEY EMPLOYEES ("COVERED PERSONS"). THE OFFICE OF GENERAL COUNSEL ANNUALLY DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE AND CONFIDENTIALITY STATEMENT ("STATEMENT") REQUIRING ALL COVERED PERSONS TO DISCLOSE INTERESTS, ROLES, AND ACTIVITIES THAT COULD GIVE RISE TO A POTENTIAL OR ACTUAL CONFLICT WITH THE INTERESTS OF DFCI. IF A TRUSTEE FAILS TO COMPLETE THE ANNUAL STATEMENT, THE CHAIR OF THE GOVERNANCE COMMITTEE MAY TAKE ACTIONS TO SUSPEND THE TRUSTEE. ADDITIONALLY, DFCI REQUIRES COVERED PERSONS TO COMPLETE THE STATEMENT UPON INITIAL APPOINTMENT TO A COVERED OFFICE AND TO UPDATE THEIR DISCLOSURES ON A CONTINUING BASIS WHENEVER A COVERED PERSON BECOMES AWARE OF A NEW OR PREVIOUSLY UNDISCLOSED INTEREST. THE OFFICE OF GENERAL COUNSEL COMPARES THE DISCLOSURES TO INSTITUTIONAL INFORMATION IN ORDER TO IDENTIFY POTENTIAL OR ACTUAL CONFLICTS OF INTEREST. THE DFCI GENERAL COUNSEL REPORTS ON ALL DISCLOSURES TO THE PRESIDENT OF DFCI, CHAIR OF THE DFCI BOARD AND CHAIR OF THE DFCI BOARD GOVERNANCE COMMITTEE. THE BOARD IS RESPONSIBLE UNDER THE COI POLICY FOR ADDRESSING ISSUES RELATED TO CONFLICTS OF COVERED PERSONS. A PROPOSED ARRANGEMENT CREATING A CONFLICT OF INTEREST MAY BE APPROVED IF APPROPRIATE STEPS ARE TAKEN TO ENSURE THAT DFCI MAKES A DECISION IN AN OBJECTIVE AND FAIR MANNER CONSISTENT WITH THE HIGHEST ETHICAL AND LEGAL STANDARDS. SUCH STEPS INCLUDE RECUSAL OF THE COVERED PERSON WITH A CONFLICT OF INTEREST FROM NEGOTIATIONS OR DISCUSSIONS ON BEHALF OF DFCI OR THE ENTITY WITH WHICH DFCI IS DOING BUSINESS AND FROM BOARD OR DFCI MANAGEMENT DISCUSSIONS OF SUCH ARRANGEMENT. Form 990, Part VI, Line 15a Process to establish compensation of top management official PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES REVIEWS THE PRESIDENT'S (DFCI'S CHIEF EXECUTIVE OFFICER) PERFORMANCE AND MAKES A RECOMMENDATION REGARDING COMPENSATION TO THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE ACTS ON THE RECOMMENDATION. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE COMPENSATION COMMITTEE ANNUALLY COMMISSIONS AN INDEPENDENT REVIEW BY A THIRD-PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE DECISION OF THE EXECUTIVE COMMITTEE IS REPORTED TO THE FULL BOARD. THE BOARD COMPLETED THIS PROCESS AS OF JANUARY 2024. Form 990, Part VI, Line 15b Process to establish compensation of other employees PROCESS FOR DETERMINING COMPENSATION OF OFFICERS AND KEY EMPLOYEES PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE DFCI PRESIDENT REVIEWS THE PERFORMANCE OF OFFICERS AND KEY EMPLOYEES. THE PRESIDENT MAKES A RECOMMENDATION AS TO THE COMPENSATION OF THOSE INDIVIDUALS WHO ARE DISQUALIFIED PERSONS OF DFCI TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES COMPENSATION FOR THOSE INDIVIDUALS BASED ON THAT RECOMMENDATION. FOR KEY EMPLOYEES WHO ARE NOT DISQUALIFIED PERSONS, THE PRESIDENT REPORTS TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES ON HIS DETERMINATION OF COMPENSATION FOR THOSE INDIVIDUALS. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE PRESIDENT AND COMPENSATION COMMITTEE ANNUALLY RECEIVE A REPORT BY A THIRD-PARTY EXECUTIVE COMPENSATION CONSULTANT. THE REPORT ANALYZES THE COMPETITIVENESS OF THE TOTAL COMPENSATION PROGRAM FOR DISQUALIFIED PERSONS AGAINST MARKET DATA REPRESENTING DFCI'S LOCAL AND NATIONAL PEER ORGANIZATIONS. THE PRESIDENT MAKES RECOMMENDATIONS FOR MARKET ADJUSTMENTS AS NEEDED FOR THOSE INDIVIDUALS WHO ARE DISQUALIFIED PERSONS OF DFCI TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES MARKET ADJUSTMENTS FOR THOSE INDIVIDUALS BASED ON THE PRESIDENT'S RECOMMENDATION. THE BOARD COMPLETED THIS PROCESS AS OF JUNE 2024. FOR KEY EMPLOYEES WHO ARE NOT DISQUALIFIED PERSONS, THE PRESIDENT REPORTS TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES ON HER DETERMINATION OF MARKET ADJUSTMENTS AS NEEDED FOR THOSE INDIVIDUALS. Form 990, Part VI, Line 19 Required documents available to the public GOVERNING DOCUMENTS: THE GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. THESE DOCUMENTS ARE ALSO AVAILABLE TO THE PUBLIC ON THE SECRETARY OF THE COMMONWEALTH'S WEBSITE. CONFLICT OF INTEREST POLICY: DFCI'S BOARD OF TRUSTEES CONFLICT OF INTEREST POLICY IS AVAILABLE UPON REQUEST. FINANCIAL STATEMENTS: THE ORGANIZATION USES THE SERVICES OF DIGITAL ASSURANCE CERTIFICATION LLC (DAC) TO REPORT ANNUAL AUDITED FINANCIAL STATEMENTS AND OTHER RELEVANT ORGANIZATIONAL INFORMATION AS REQUIRED BY CERTAIN REGULATORY AND TAX LAWS. DAC IS A WEBSITE (WWW.DACBOND.COM) FREE TO THE PUBLIC THAT PUBLISHES TAX-EXEMPT BOND ISSUERS' FINANCIAL AND LEGAL DOCUMENTS SUCH AS THE AUDITED FINANCIAL STATEMENTS. FISCAL YEAR 2016 THROUGH THE LATEST ISSUE DATE OF THE AUDITED FINANCIAL STATEMENTS FOR DANA-FARBER CANCER INSTITUTE, INC. CAN BE FOUND ON THE DAC WEBSITE. ANNUAL AUDITED FINANCIAL STATEMENTS FROM FISCAL YEAR 1998 THROUGH FISCAL YEAR 2015 ARE AVAILABLE UPON REQUEST. Form 990, Part VII, Section B, Line 1 INDEPENDENT CONTRACTORS THE AMOUNT PAID TO WALSH BROTHERS, INC. INCLUDED COSTS FOR BUILDING SERVICES AND MATERIALS. HOWEVER, THE ORGANIZATION WAS UNABLE TO OBTAIN INFORMATION TO BREAKOUT THE EXACT AMOUNT FOR MATERIAL COSTS. Form 990, Part VIII, Line 11d Other Miscellaneous Revenue All Other - Total Revenue: 4177938, Related or Exempt Function Revenue: , Unrelated Business Revenue: , Revenue Excluded from Tax Under Sections 512, 513, or 514: 4177938; Form 990, Part XI, Line 9 Other changes in net assets or fund balances CHANGE IN INTEREST IN ASSETS HELD BY AFFILIATES - XXX-XX-XXXX; CHANGE IN VALUE OF SWAP AGREEMENT - 23437757; PENSION ADJUSTMENT - -59494; Total - XXX-XX-XXXX; DANA-FARBER GLOBAL ONCOLOGY LLC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 851914853 INTERNATIONAL ONCOLOGY MA 1970857 11359146 DFCI BINNEY STREET CAPITAL FUND LLC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 INVESTMENTS DE -723743 7339663 DFI Dana-Farber National Workforce LLC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 921748999 Professional employer organization MA 0 0 DFCI DANA-FARBER INC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 043102433 INVESTMENT MANAGEMENT MA 501(c)(3) Type I DFCI true THE DANA-FARBER TRUST INC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 300195757 RECEIVE REAL ESTATE GIFTS FOR DFCI MA 501(c)(3) Type I DFCI true DANA-FARBERMASS GEN BRIGHAM CANCER CARE 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 043320640 ONCOLOGY RESEARCH MA 501(c)(3) Type I NA false RMSA TRUST 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 562656539 VEBA TRUST MA 501(c)(9) DFCI true FRIENDS OF DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 371613621 FUNDRAISING MA 501(c)(3) Type I DFCI true DANA-FARBERCHILDREN'S HOSP CANCER CARE 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 043554536 PEDIATRIC ONCOLOGY MA 501(c)(3) Type I NA false DANA-FARBER CANCER CARE NETWORK INC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 465138314 ONCOLOGY CARE MA 501(c)(3) 10 DFCI true MGB DF INTL LLC 399 REVOLUTION DR STE 645 SOMERVILLE MA 02145 871595882 INTERNATIONAL CONSULTING DE NA N/A -23251 -167361 false false 0.5 false false true false false false false false false false false false false false true false false true true Dana-Farber Inc R 105918323 Cash Dana-Farber Inc S 465246292 Cash Friends of Dana-Farber Cancer Institute Inc C 1340898 Cash Friends of Dana-Farber Cancer Institute Inc O 323495 Actual Exp RMSA Trust R 820889 Cash Dana-Farber Cancer Care Network Inc S 1522980 Cash